EcoDrugPlus

Erb-B2 Receptor Tyrosine Kinase 3b

Ensembl ID : ENSTNIG00000015062
Gene Symbol: ERBB3B
2 Cross references
206 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSTNIG00000016436
Gene Symbol: ERBB4
2 Cross references
47 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4a

Ensembl ID : ENSTNIG00000008323
Gene Symbol: ERBB4A
2 Cross references
230 Possible Orthologues:

Estrogen Receptor 1

Ensembl ID : ENSTNIG00000012264
Gene Symbol: ESR1
2 Cross references
215 Possible Orthologues:

Estrogen Receptor 2a

Ensembl ID : ENSTNIG00000003064
Gene Symbol: ESR2A
2 Cross references
198 Possible Orthologues:

Estrogen Receptor 2b

Ensembl ID : ENSTNIG00000012382
Gene Symbol: ESR2B
2 Cross references
207 Possible Orthologues:

Estrogen-Related Receptor Gamma A

Ensembl ID : ENSTNIG00000017714
Gene Symbol: ESRRGA
2 Cross references
198 Possible Orthologues:

Exportin 1

Ensembl ID : ENSTNIG00000003360
Gene Symbol: XPO1
2 Cross references
224 Possible Orthologues:

Farnesyl Diphosphate Synthase (Farnesyl Pyrophosphate Synthetase, Dimethylallyltranstransferase, Geranyltranstransferase)

Ensembl ID : ENSTNIG00000018318
Gene Symbol: FDPS
2 Cross references
267 Possible Orthologues:

Farnesyl-Diphosphate Farnesyltransferase 1

Ensembl ID : ENSTNIG00000016370
Gene Symbol: FDFT1
2 Cross references
220 Possible Orthologues:

Farnesyltransferase, Caax Box, Alpha

Ensembl ID : ENSTNIG00000006078
Gene Symbol: FNTA
2 Cross references
221 Possible Orthologues:

Farnesyltransferase, Caax Box, Beta

Ensembl ID : ENSTNIG00000016413
Gene Symbol: FNTB
2 Cross references
209 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).